Organisation paid for research Program year 2024 Source: CMS Open Payments

C-1 Headlands, LLC

Neither a doctor nor a teaching hospital

Research payments

$9,484,669

412 payments

Through program year 2024, C-1 Headlands, LLC is reported as receiving $9,484,669 in research payments, across 412 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $576 1
2023 Research $16,849 7
2022 Research $1,395,157 148
2021 Research $4,403,921 230
2020 Research $3,668,166 26

Breakdown

Who paid Research payments · program years 2020–2024
  1. Janssen Research & Development, LLC $6,850,757 339 payments
  2. AstraZeneca Pharmaceuticals LP $2,328,653 8 payments
  3. Janssen Pharmaceuticals, Inc $188,898 47 payments
  4. Exeltis, USA Inc. $77,946 1 payment
  5. Alnylam Pharmaceuticals Inc. $25,882 16 payments
  6. Flexion Therapeutics, Inc. $12,534 1 payment
Studies the money was for Research payments · program years 2020–2024
  1. A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults $5,601,723 323 payments
  2. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $2,325,893 4 payments
  3. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults $1,249,034 16 payments
  4. A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older $188,898 47 payments
  5. A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability ofLPRI-424, 13 Cycles $77,946 1 payment
  6. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) $25,882 16 payments
  7. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis $12,534 1 payment
  8. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $1,827 2 payments
  9. A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $933 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record